Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial...

Area of Science:

• Pharmacology
• Mental Health
• Public Health

Background:

• Depression is a prevalent and costly mental disorder requiring improved treatment strategies.
• Non-adherence to treatment and guidelines limit the effectiveness of depression pharmacotherapy.
• Community pharmacists can play a vital role in enhancing patient compliance and well-being through pharmaceutical care.

Purpose of the Study:

• To evaluate the effectiveness of a community pharmacist intervention designed to improve adherence and outcomes for primary care patients with depression.
• To assess the cost-effectiveness of this pharmaceutical care support program.

Main Methods:

• A 6-month randomized controlled trial involving 194 primary care patients (aged 18-75) diagnosed with depressive disorder.
• Intervention group received a pharmaceutical care support program; control group received usual care.
• Measurements included antidepressant compliance, depression severity (PHQ-9), anxiety (STAI-S), quality of life (EuroQol-5D), and healthcare service utilization (CSRI).

Main Results:

• The study is designed to measure compliance with antidepressants as the primary outcome.
• Secondary outcomes include changes in depression and anxiety severity, quality of life, and patient satisfaction.
• Healthcare and social care service utilization will also be assessed.

Conclusions:

• This trial will yield crucial data on the effectiveness of a community pharmacist-led intervention for depression management.
• Findings will inform healthcare professionals and policymakers about the value of pharmaceutical care in primary care settings.
• The study will determine the cost-effectiveness of the intervention, aiding resource allocation decisions.